CU24532B1 - Anticuerpos anti-transtiretina - Google Patents
Anticuerpos anti-transtiretinaInfo
- Publication number
- CU24532B1 CU24532B1 CU2017000096A CU20170096A CU24532B1 CU 24532 B1 CU24532 B1 CU 24532B1 CU 2017000096 A CU2017000096 A CU 2017000096A CU 20170096 A CU20170096 A CU 20170096A CU 24532 B1 CU24532 B1 CU 24532B1
- Authority
- CU
- Cuba
- Prior art keywords
- antibodies
- chain cdrs
- transtiretin
- ttr
- heavy chain
- Prior art date
Links
- 108010071690 Prealbumin Proteins 0.000 abstract 3
- 102000009190 Transthyretin Human genes 0.000 abstract 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109001P | 2015-01-28 | 2015-01-28 | |
| US201562266557P | 2015-12-11 | 2015-12-11 | |
| PCT/IB2016/050414 WO2016120809A1 (en) | 2015-01-28 | 2016-01-28 | Anti-transthyretin antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20170096A7 CU20170096A7 (es) | 2018-03-13 |
| CU24532B1 true CU24532B1 (es) | 2021-07-02 |
Family
ID=55361912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2017000096A CU24532B1 (es) | 2015-01-28 | 2016-01-28 | Anticuerpos anti-transtiretina |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20160257736A1 (enExample) |
| EP (1) | EP3250594B1 (enExample) |
| JP (2) | JP6875280B2 (enExample) |
| KR (1) | KR102619359B1 (enExample) |
| CN (1) | CN107428822B (enExample) |
| AU (1) | AU2016210887B2 (enExample) |
| CA (1) | CA2974911A1 (enExample) |
| CO (1) | CO2017008469A2 (enExample) |
| CU (1) | CU24532B1 (enExample) |
| EA (1) | EA036048B1 (enExample) |
| ES (1) | ES2905311T3 (enExample) |
| MX (1) | MX391789B (enExample) |
| MY (1) | MY193674A (enExample) |
| PE (1) | PE20180200A1 (enExample) |
| SA (1) | SA517381991B1 (enExample) |
| SG (1) | SG11201706125QA (enExample) |
| TW (2) | TWI718121B (enExample) |
| WO (1) | WO2016120809A1 (enExample) |
| ZA (1) | ZA201705662B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| TWI718121B (zh) * | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3478716A2 (en) * | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007923A2 (en) * | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3478714A2 (en) * | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3585162B1 (en) | 2017-09-29 | 2023-08-30 | Regeneron Pharmaceuticals, Inc. | Rodents comprising a humanized ttr locus and methods of use |
| AU2018345806A1 (en) | 2017-10-06 | 2020-03-12 | Novo Nordisk A/S | Anti-transthyretin antibodies |
| JP7292569B2 (ja) * | 2017-10-06 | 2023-06-19 | ノボ ノルディスク エー／エス | トランスサイレチンを検出する方法 |
| PE20211453A1 (es) | 2017-11-29 | 2021-08-05 | Prothena Biosciences Ltd | Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina |
| WO2020247452A1 (en) * | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| CN112816453B (zh) * | 2021-02-09 | 2022-07-08 | 黑龙江大学 | 蛋白在预测药物性能上的应用 |
| WO2025125544A1 (en) | 2023-12-15 | 2025-06-19 | Novo Nordisk A/S | Stable liquid formulations |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| CA2361492A1 (en) | 1999-02-05 | 2000-08-10 | Samsung Electronics Co., Ltd. | Image texture retrieving method and apparatus thereof |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| EP1470146B8 (en) | 2001-12-28 | 2007-09-12 | Amgen Fremont Inc. | Antibodies against the muc18 antigen |
| MXPA05005481A (es) | 2002-11-29 | 2005-07-25 | Boehringer Ingelheim Pharma | Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada. |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| PT1820022E (pt) | 2004-11-10 | 2009-08-05 | Boehringer Ingelheim Pharma | Utilização de análise por citometria de fluxo para optimizar estratégias de conservação de bancos de células cho |
| US8703096B2 (en) | 2006-04-21 | 2014-04-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Beta-amyloid PET imaging agents |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
| WO2008107388A1 (en) | 2007-03-02 | 2008-09-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Improvement of protein production |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| WO2010030203A1 (en) * | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| JP2016514091A (ja) * | 2013-02-08 | 2016-05-19 | ミスフォールディング ダイアグノスティクス， インコーポレイテッド | トランスサイレチン抗体およびその使用 |
| TWI718121B (zh) * | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
-
2016
- 2016-01-27 TW TW105102534A patent/TWI718121B/zh not_active IP Right Cessation
- 2016-01-27 TW TW110100084A patent/TWI781507B/zh active
- 2016-01-28 SG SG11201706125QA patent/SG11201706125QA/en unknown
- 2016-01-28 PE PE2017001286A patent/PE20180200A1/es unknown
- 2016-01-28 CA CA2974911A patent/CA2974911A1/en active Pending
- 2016-01-28 US US15/009,666 patent/US20160257736A1/en not_active Abandoned
- 2016-01-28 JP JP2017540249A patent/JP6875280B2/ja active Active
- 2016-01-28 EA EA201791711A patent/EA036048B1/ru unknown
- 2016-01-28 AU AU2016210887A patent/AU2016210887B2/en active Active
- 2016-01-28 CU CU2017000096A patent/CU24532B1/es unknown
- 2016-01-28 KR KR1020177023748A patent/KR102619359B1/ko active Active
- 2016-01-28 MY MYPI2017702749A patent/MY193674A/en unknown
- 2016-01-28 WO PCT/IB2016/050414 patent/WO2016120809A1/en not_active Ceased
- 2016-01-28 MX MX2017009804A patent/MX391789B/es unknown
- 2016-01-28 ES ES16704940T patent/ES2905311T3/es active Active
- 2016-01-28 CN CN201680015800.8A patent/CN107428822B/zh active Active
- 2016-01-28 EP EP16704940.2A patent/EP3250594B1/en active Active
-
2017
- 2017-07-26 SA SA517381991A patent/SA517381991B1/ar unknown
- 2017-08-21 ZA ZA2017/05662A patent/ZA201705662B/en unknown
- 2017-08-22 CO CONC2017/0008469A patent/CO2017008469A2/es unknown
-
2021
- 2021-04-22 JP JP2021072547A patent/JP7219928B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI781507B (zh) | 2022-10-21 |
| EA201791711A1 (ru) | 2017-11-30 |
| CO2017008469A2 (es) | 2018-01-16 |
| AU2016210887B2 (en) | 2021-11-04 |
| AU2016210887A1 (en) | 2017-08-10 |
| KR20170120607A (ko) | 2017-10-31 |
| EP3250594B1 (en) | 2021-11-17 |
| CN107428822B (zh) | 2021-11-23 |
| MX2017009804A (es) | 2018-08-15 |
| EA036048B1 (ru) | 2020-09-18 |
| EP3250594A1 (en) | 2017-12-06 |
| TW202118782A (zh) | 2021-05-16 |
| JP6875280B2 (ja) | 2021-05-26 |
| CN107428822A (zh) | 2017-12-01 |
| TWI718121B (zh) | 2021-02-11 |
| KR102619359B1 (ko) | 2024-01-02 |
| CA2974911A1 (en) | 2016-08-04 |
| ZA201705662B (en) | 2018-08-29 |
| JP7219928B2 (ja) | 2023-02-09 |
| SG11201706125QA (en) | 2017-08-30 |
| ES2905311T3 (es) | 2022-04-07 |
| TW201636372A (zh) | 2016-10-16 |
| PE20180200A1 (es) | 2018-01-31 |
| JP2021129562A (ja) | 2021-09-09 |
| BR112017016324A2 (pt) | 2018-03-27 |
| MX391789B (es) | 2025-03-21 |
| CU20170096A7 (es) | 2018-03-13 |
| SA517381991B1 (ar) | 2021-12-13 |
| US20160257736A1 (en) | 2016-09-08 |
| JP2018509889A (ja) | 2018-04-12 |
| MY193674A (en) | 2022-10-24 |
| WO2016120809A1 (en) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24532B1 (es) | Anticuerpos anti-transtiretina | |
| CY1122245T1 (el) | Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου | |
| CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
| CY1122840T1 (el) | Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3 | |
| CO2017013356A2 (es) | Anticuerpos de factor xi | |
| CL2018001177A1 (es) | Anticuerpos vinculados especificamente a pd-1 y sus usos. | |
| PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
| EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
| ZA201803079B (en) | Anti-dr5 antibodies and methods of use thereof | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| NZ728749A (en) | Anti-pd-l1 antibodies | |
| EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
| EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| CY1125400T1 (el) | Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων | |
| NZ608206A (en) | Antibodies that bind myostatin, compositions and methods | |
| AR100680A1 (es) | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos | |
| CY1121158T1 (el) | Αντισωμα ικανο να αναγνωριζει ειδικα υποδοχεα τρανσφερρινης | |
| AR100978A1 (es) | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS | |
| CL2017000912A1 (es) | Anticuerpos que se unen a ccr6 y sus usos | |
| MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
| PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof |